

Diego Salas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6699926/publications.pdf>

Version: 2024-02-01

15
papers

383
citations

1478280

6
h-index

1372474

10
g-index

17
all docs

17
docs citations

17
times ranked

684
citing authors

#	ARTICLE	IF	CITATIONS
1	Paradigms on Immunotherapy Combinations with Chemotherapy. <i>Cancer Discovery</i> , 2021, 11, 1353-1367.	7.7	197
2	Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. <i>Cancer Research</i> , 2017, 77, 3672-3684.	0.4	99
3	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. <i>Tumor Biology</i> , 2016, 37, 13687-13694.	0.8	37
4	The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes. <i>British Journal of Cancer</i> , 2021, 124, 1138-1149.	2.9	14
5	Inflammation and immunity in ovarian cancer. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 56-66.	2.2	12
6	The BRCA Gene in Epithelial Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1235.	1.7	9
7	Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack. <i>Clinical Cancer Research</i> , 2019, 25, 5435-5437.	3.2	5
8	Pazopanib-induced asymptomatic radiological acute pancreatitis: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 6, 651-654.	0.4	3
9	Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. <i>PLoS ONE</i> , 2019, 14, e0215970.	1.1	3
10	Single-Institution Experience in Clinical Trials During the COVID-19 Pandemic in Spain: Not So Bad After All?. <i>JCO Global Oncology</i> , 2020, 6, 904-905.	0.8	3
11	Id1 and Id3 genes confer poor prognosis in KRAS-mutant (KM) lung adenocarcinoma (LA) patients. Gene silencing reduces metastatic rate to the liver and increases survival. <i>Annals of Oncology</i> , 2016, 27, vi440.	0.6	0
12	Preselecting tumour-infiltrating lymphocyte subsets to implement adoptive immunotherapy in ovarian cancer. <i>Annals of Oncology</i> , 2019, 30, v419.	0.6	0
13	Bevacizumab plus irinotecan in patients with recurrent high grade malignant gliomas.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13057-e13057.	0.8	0
14	Abstract P6-07-32: Vitamin D as a potential biomarker of aggressiveness in non-metastatic breast cancer. , 2017, , .		0
15	A population model to predict progression free survival in breast cancer patients treated with neoadjuvant chemotherapy ± vaccines based on tumour growth inhibition metrics.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12114-e12114.	0.8	0